CalciMedica (NASDAQ:CALC) Price Target Cut to $16.00 by Analysts at HC Wainwright

CalciMedica (NASDAQ:CALC) had its price target lowered by HC Wainwright from $20.00 to $16.00 in a report issued on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Oppenheimer increased their target price on CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th.

CalciMedica Price Performance

NASDAQ:CALC opened at $3.50 on Monday. CalciMedica has a one year low of $2.68 and a one year high of $8.38. The company’s 50-day simple moving average is $4.25 and its 200 day simple moving average is $4.63.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. On average, equities research analysts anticipate that CalciMedica will post -2.21 EPS for the current year.

Insider Activity

In other news, Director Robert N. Wilson acquired 54,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the acquisition, the director now directly owns 364,196 shares in the company, valued at approximately $1,354,809.12. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Eric W. Roberts acquired 53,333 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, with a total value of $199,998.75. Following the completion of the acquisition, the insider now directly owns 164,706 shares of the company’s stock, valued at approximately $617,647.50. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert N. Wilson acquired 54,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were bought at an average price of $3.72 per share, for a total transaction of $200,880.00. Following the transaction, the director now owns 364,196 shares of the company’s stock, valued at $1,354,809.12. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 138,333 shares of company stock worth $518,119 over the last 90 days. 41.55% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc boosted its position in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.